Kelu Li, Ping-ping Ning, Bin Liu, Hongju Yang, Yongyun Zhu, Weifang Yin, Chuanbin Zhou, Hui Ren, Xinglong Yang
{"title":"CHCHD2的下调可能通过减少NFE2L2和RQCD1的表达而导致帕金森病。","authors":"Kelu Li, Ping-ping Ning, Bin Liu, Hongju Yang, Yongyun Zhu, Weifang Yin, Chuanbin Zhou, Hui Ren, Xinglong Yang","doi":"10.2174/1567202619666220406082221","DOIUrl":null,"url":null,"abstract":"BACKGROUND\nParkinson's disease (PD) is associated with coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) downregulation, which has been linked to reduced cyclocytase activity and increased levels of oxygen free radicals, leading to mitochondrial fragmentation and apoptosis. Little is known about how CHCHD2 normally functions in the cell and, therefore, how its downregulation may contribute to PD.\n\n\nOBJECTIVE\nThis study aimed to identify such target genes using chromatin immunoprecipitation sequencing from SH-SY5Y human neuroblastoma cells treated with neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model.\n\n\nMETHODS\nIn this study, we established a MPP+ -reated SH-SY5Y cell model and evaluated the effects of CHCHD2 overexpression on cell proliferation and apoptosis. At the same time, we used high-throughput chromatin immunoprecipitation sequencing to identify its downstream target gene in SH-SY5Y cells. In addition, we verified the possible downstream target genes and discussed their mechanisms.\n\n\nRESULTS\nThe expression level of α-synuclein increased in SH-SY5Y cells treated with MPP+, while the protein expression level of CHCHD2 decreased significantly, especially after 24 h of treatment. Chip-IP results showed that CHCHD2 may regulate potential target genes such as HDX, ACP1, RAVER2, C1orf229, RN7SL130, GNPTG, erythroid 2 Like 2 (NFE2L2), required for cell differentiation 1 homologue (RQCD1), solute carrier family 5 member 7 (SLA5A7), and N-Acetyltransferase 8 Like (NAT8L). NFE2L2 and RQCD1 were validated as targets using PCR and western blotting of immunoprecipitates, and these two genes together with SLA5A7 and NAT8L were upregulated in SH-SY5Y cells overexpressing CHCHD2. Downregulation of CHCHD2 may contribute to PD by leading to inadequate expression of NFE2L2 and RQCD1 as well as, potentially, SLA5A7 and NAT8L.\n\n\nCONCLUSION\nOur results suggest that CHCHD2 plays a protective role by maintaining mitochondrial homeostasis and promoting proliferation in neurons. In this study, the changes of CHCHD2 and downstream target genes such as NFE2L2/RQCD1 may have potential application prospects in the future. These findings provide leads to explore PD pathogenesis and potential treatments.","PeriodicalId":10879,"journal":{"name":"Current neurovascular research","volume":" ","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Downregulation of CHCHD2 may Contribute to Parkinson's Disease by Reducing Expression of NFE2L2 and RQCD1.\",\"authors\":\"Kelu Li, Ping-ping Ning, Bin Liu, Hongju Yang, Yongyun Zhu, Weifang Yin, Chuanbin Zhou, Hui Ren, Xinglong Yang\",\"doi\":\"10.2174/1567202619666220406082221\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND\\nParkinson's disease (PD) is associated with coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) downregulation, which has been linked to reduced cyclocytase activity and increased levels of oxygen free radicals, leading to mitochondrial fragmentation and apoptosis. Little is known about how CHCHD2 normally functions in the cell and, therefore, how its downregulation may contribute to PD.\\n\\n\\nOBJECTIVE\\nThis study aimed to identify such target genes using chromatin immunoprecipitation sequencing from SH-SY5Y human neuroblastoma cells treated with neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model.\\n\\n\\nMETHODS\\nIn this study, we established a MPP+ -reated SH-SY5Y cell model and evaluated the effects of CHCHD2 overexpression on cell proliferation and apoptosis. At the same time, we used high-throughput chromatin immunoprecipitation sequencing to identify its downstream target gene in SH-SY5Y cells. In addition, we verified the possible downstream target genes and discussed their mechanisms.\\n\\n\\nRESULTS\\nThe expression level of α-synuclein increased in SH-SY5Y cells treated with MPP+, while the protein expression level of CHCHD2 decreased significantly, especially after 24 h of treatment. Chip-IP results showed that CHCHD2 may regulate potential target genes such as HDX, ACP1, RAVER2, C1orf229, RN7SL130, GNPTG, erythroid 2 Like 2 (NFE2L2), required for cell differentiation 1 homologue (RQCD1), solute carrier family 5 member 7 (SLA5A7), and N-Acetyltransferase 8 Like (NAT8L). NFE2L2 and RQCD1 were validated as targets using PCR and western blotting of immunoprecipitates, and these two genes together with SLA5A7 and NAT8L were upregulated in SH-SY5Y cells overexpressing CHCHD2. Downregulation of CHCHD2 may contribute to PD by leading to inadequate expression of NFE2L2 and RQCD1 as well as, potentially, SLA5A7 and NAT8L.\\n\\n\\nCONCLUSION\\nOur results suggest that CHCHD2 plays a protective role by maintaining mitochondrial homeostasis and promoting proliferation in neurons. In this study, the changes of CHCHD2 and downstream target genes such as NFE2L2/RQCD1 may have potential application prospects in the future. These findings provide leads to explore PD pathogenesis and potential treatments.\",\"PeriodicalId\":10879,\"journal\":{\"name\":\"Current neurovascular research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2022-04-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current neurovascular research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/1567202619666220406082221\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current neurovascular research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1567202619666220406082221","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:帕金森病(PD)与含2螺旋结构域(CHCHD2)下调有关,这与环切酶活性降低和氧自由基水平升高有关,导致线粒体断裂和凋亡。关于CHCHD2在细胞中的正常功能以及其下调如何导致PD,我们知之甚少。目的利用神经毒素1-甲基-4-苯基吡啶(MPP+)处理的SH-SY5Y人神经母细胞瘤细胞的染色质免疫沉淀测序,鉴定PD模型中的靶基因。方法建立MPP+诱导SH-SY5Y细胞模型,观察CHCHD2过表达对SH-SY5Y细胞增殖和凋亡的影响。同时,我们利用高通量染色质免疫沉淀测序鉴定其在SH-SY5Y细胞中的下游靶基因。此外,我们还验证了可能的下游靶基因,并讨论了它们的作用机制。结果经MPP+处理的SH-SY5Y细胞α-synuclein表达水平升高,而CHCHD2蛋白表达水平明显降低,尤其是处理24 h后。Chip-IP结果显示,CHCHD2可能调控HDX、ACP1、RAVER2、C1orf229、RN7SL130、GNPTG、红细胞2 Like 2 (NFE2L2)、细胞分化1同源物(RQCD1)、溶质载体家族5成员7 (SLA5A7)和n -乙酰转移酶8 Like (NAT8L)等潜在靶基因。通过PCR和免疫沉淀的western blotting验证了NFE2L2和RQCD1是靶点,这两个基因与SLA5A7和NAT8L在过表达CHCHD2的SH-SY5Y细胞中表达上调。CHCHD2的下调可能通过导致NFE2L2和RQCD1以及潜在的SLA5A7和NAT8L的表达不足而导致PD。结论CHCHD2通过维持线粒体稳态和促进神经元增殖发挥保护作用。在本研究中,CHCHD2及下游靶基因如NFE2L2/RQCD1的变化在未来可能具有潜在的应用前景。这些发现为探索帕金森病的发病机制和潜在的治疗提供了线索。
Downregulation of CHCHD2 may Contribute to Parkinson's Disease by Reducing Expression of NFE2L2 and RQCD1.
BACKGROUND
Parkinson's disease (PD) is associated with coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) downregulation, which has been linked to reduced cyclocytase activity and increased levels of oxygen free radicals, leading to mitochondrial fragmentation and apoptosis. Little is known about how CHCHD2 normally functions in the cell and, therefore, how its downregulation may contribute to PD.
OBJECTIVE
This study aimed to identify such target genes using chromatin immunoprecipitation sequencing from SH-SY5Y human neuroblastoma cells treated with neurotoxin 1-methyl-4-phenylpyridinium (MPP+) as a PD model.
METHODS
In this study, we established a MPP+ -reated SH-SY5Y cell model and evaluated the effects of CHCHD2 overexpression on cell proliferation and apoptosis. At the same time, we used high-throughput chromatin immunoprecipitation sequencing to identify its downstream target gene in SH-SY5Y cells. In addition, we verified the possible downstream target genes and discussed their mechanisms.
RESULTS
The expression level of α-synuclein increased in SH-SY5Y cells treated with MPP+, while the protein expression level of CHCHD2 decreased significantly, especially after 24 h of treatment. Chip-IP results showed that CHCHD2 may regulate potential target genes such as HDX, ACP1, RAVER2, C1orf229, RN7SL130, GNPTG, erythroid 2 Like 2 (NFE2L2), required for cell differentiation 1 homologue (RQCD1), solute carrier family 5 member 7 (SLA5A7), and N-Acetyltransferase 8 Like (NAT8L). NFE2L2 and RQCD1 were validated as targets using PCR and western blotting of immunoprecipitates, and these two genes together with SLA5A7 and NAT8L were upregulated in SH-SY5Y cells overexpressing CHCHD2. Downregulation of CHCHD2 may contribute to PD by leading to inadequate expression of NFE2L2 and RQCD1 as well as, potentially, SLA5A7 and NAT8L.
CONCLUSION
Our results suggest that CHCHD2 plays a protective role by maintaining mitochondrial homeostasis and promoting proliferation in neurons. In this study, the changes of CHCHD2 and downstream target genes such as NFE2L2/RQCD1 may have potential application prospects in the future. These findings provide leads to explore PD pathogenesis and potential treatments.
期刊介绍:
Current Neurovascular Research provides a cross platform for the publication of scientifically rigorous research that addresses disease mechanisms of both neuronal and vascular origins in neuroscience. The journal serves as an international forum publishing novel and original work as well as timely neuroscience research articles, full-length/mini reviews in the disciplines of cell developmental disorders, plasticity, and degeneration that bridges the gap between basic science research and clinical discovery. Current Neurovascular Research emphasizes the elucidation of disease mechanisms, both cellular and molecular, which can impact the development of unique therapeutic strategies for neuronal and vascular disorders.